December 20, 2017
Not intended for U.S. and UK Media
- Overview
- Bayer Group
- Stock
- Bonds
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Investor News 2017
December 13, 2017
Not intended for U.S. and UK Media
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer
moreDecember 11, 2017
Not intended for U.S. and UK Media
Bayer's rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
moreDecember 04, 2017
Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research:
Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers
moreNovember 30, 2017
Not intended for U.S. and UK Media
Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early
moreNovember 24, 2017
Not intended for U.S. and UK Media
Phase III study program with Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority
moreNovember 14, 2017
Not intended for U.S. and UK Media
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
moreNovember 06, 2017
Not intended for U.S. and UK Media